Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088681832> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W3088681832 endingPage "S1097" @default.
- W3088681832 startingPage "S1097" @default.
- W3088681832 abstract "Type 2 diabetes and metabolic syndrome are negative prognostic factors in breast cancer patients. Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, achieving unprecedented efficacy in multiple malignancies. We aimed to study if hyperglycemia could enhance ICI-induced cardiotoxicity in cardiomyocites and immunoresistance in human breast cancer cells. Finally, we evaluated if the treatment with an SGLT-2 inhibitor (empagliflozin) could revert these effects during hyperglycemic condition. Human cardiomyocytes (HL-1 cells) and PD-1+ ERɑ+, PR+, HER2- breast cancer cells (MCF-7 cell line) were exposed to nivolumab (100 nM) at high glucose (25 mM) low glucose (5.5 mM) for 72 h. After the incubation period, we performed the following tests: determination of cell viability, through analysis of mitochondrial dehydrogenase activity; NLRP3, p65/NF-kB and leukotrienes expression through ELISA method. Nivolumab-induced cardiotoxicity was enhanced by 2,7-fold during exposure to 25 mM glucose (High Glucose; HG) compared to 5.5 mM glucose (Low Glucose; LG) in human adult cardiomyocytes. Moreover, IC50 value of nivolumab against MCF7-cells increased significantly under HG vs LG (P<0.01). Moreover, during high glucose condition, cardiomyocytes and human breast cancer cells exposed to nivolumab, increases the expression of NLRP3, p65/NF-kB, leukotrienes and cytokines. Notably, hyperglycemia increases significantly the intracellular calcium (iCa2+) content in cardiomyocytes during incubation with nivolumab, probably increasing the metabolic susceptibility to damages induced by ICI. Shifting from HG to LG, as well as the administration of 50 nM empagliflozin reduced the magnitude of cardiotoxic effects, indicating cardioprotective and immuno-enhancing properties. To our knowledge these results are the first evidence that hyperglycemia exacerbates ICI-induced cardiotoxicity and immunoresistace and set the stage to preclinical and clinical trials aimed to decrease glucose through dietary or lifestyle changes or through new hypoglycemic drugs (gliflozins)." @default.
- W3088681832 created "2020-10-01" @default.
- W3088681832 creator A5009029772 @default.
- W3088681832 creator A5013631294 @default.
- W3088681832 creator A5018142949 @default.
- W3088681832 creator A5023150524 @default.
- W3088681832 creator A5048066085 @default.
- W3088681832 creator A5061448677 @default.
- W3088681832 creator A5069310507 @default.
- W3088681832 creator A5075134017 @default.
- W3088681832 date "2020-09-01" @default.
- W3088681832 modified "2023-10-16" @default.
- W3088681832 title "1944P Hyperglycemia increased nivolumab-induced cardiotoxicity, enhanced immunoresistance of ERɑ+, PR+, HER2- breast cancer cells modulating growth factors and NLRP3 expression" @default.
- W3088681832 doi "https://doi.org/10.1016/j.annonc.2020.08.1336" @default.
- W3088681832 hasPublicationYear "2020" @default.
- W3088681832 type Work @default.
- W3088681832 sameAs 3088681832 @default.
- W3088681832 citedByCount "1" @default.
- W3088681832 countsByYear W30886818322021 @default.
- W3088681832 crossrefType "journal-article" @default.
- W3088681832 hasAuthorship W3088681832A5009029772 @default.
- W3088681832 hasAuthorship W3088681832A5013631294 @default.
- W3088681832 hasAuthorship W3088681832A5018142949 @default.
- W3088681832 hasAuthorship W3088681832A5023150524 @default.
- W3088681832 hasAuthorship W3088681832A5048066085 @default.
- W3088681832 hasAuthorship W3088681832A5061448677 @default.
- W3088681832 hasAuthorship W3088681832A5069310507 @default.
- W3088681832 hasAuthorship W3088681832A5075134017 @default.
- W3088681832 hasBestOaLocation W30886818321 @default.
- W3088681832 hasConcept C121608353 @default.
- W3088681832 hasConcept C126322002 @default.
- W3088681832 hasConcept C134018914 @default.
- W3088681832 hasConcept C203014093 @default.
- W3088681832 hasConcept C2775887513 @default.
- W3088681832 hasConcept C2776694085 @default.
- W3088681832 hasConcept C2777180221 @default.
- W3088681832 hasConcept C2777701055 @default.
- W3088681832 hasConcept C2778233292 @default.
- W3088681832 hasConcept C2780030458 @default.
- W3088681832 hasConcept C502942594 @default.
- W3088681832 hasConcept C530470458 @default.
- W3088681832 hasConcept C555293320 @default.
- W3088681832 hasConcept C71924100 @default.
- W3088681832 hasConcept C8891405 @default.
- W3088681832 hasConcept C96232424 @default.
- W3088681832 hasConcept C98274493 @default.
- W3088681832 hasConceptScore W3088681832C121608353 @default.
- W3088681832 hasConceptScore W3088681832C126322002 @default.
- W3088681832 hasConceptScore W3088681832C134018914 @default.
- W3088681832 hasConceptScore W3088681832C203014093 @default.
- W3088681832 hasConceptScore W3088681832C2775887513 @default.
- W3088681832 hasConceptScore W3088681832C2776694085 @default.
- W3088681832 hasConceptScore W3088681832C2777180221 @default.
- W3088681832 hasConceptScore W3088681832C2777701055 @default.
- W3088681832 hasConceptScore W3088681832C2778233292 @default.
- W3088681832 hasConceptScore W3088681832C2780030458 @default.
- W3088681832 hasConceptScore W3088681832C502942594 @default.
- W3088681832 hasConceptScore W3088681832C530470458 @default.
- W3088681832 hasConceptScore W3088681832C555293320 @default.
- W3088681832 hasConceptScore W3088681832C71924100 @default.
- W3088681832 hasConceptScore W3088681832C8891405 @default.
- W3088681832 hasConceptScore W3088681832C96232424 @default.
- W3088681832 hasConceptScore W3088681832C98274493 @default.
- W3088681832 hasLocation W30886818321 @default.
- W3088681832 hasOpenAccess W3088681832 @default.
- W3088681832 hasPrimaryLocation W30886818321 @default.
- W3088681832 hasRelatedWork W1966504330 @default.
- W3088681832 hasRelatedWork W1979139803 @default.
- W3088681832 hasRelatedWork W2037631372 @default.
- W3088681832 hasRelatedWork W2378785636 @default.
- W3088681832 hasRelatedWork W2748952813 @default.
- W3088681832 hasRelatedWork W3088681832 @default.
- W3088681832 hasRelatedWork W4283731173 @default.
- W3088681832 hasRelatedWork W4291367166 @default.
- W3088681832 hasRelatedWork W4304116770 @default.
- W3088681832 hasRelatedWork W4308359949 @default.
- W3088681832 hasVolume "31" @default.
- W3088681832 isParatext "false" @default.
- W3088681832 isRetracted "false" @default.
- W3088681832 magId "3088681832" @default.
- W3088681832 workType "article" @default.